APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-L1 Biomarker Testing

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

Selected research

Market Structure

Global PD-L1 Biomarker Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025193 pages

Choose your research edition.

Industry ResearchPD-L1 Biomarker Testing Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-L1 Biomarker Testing Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal PD-L1 Biomarker Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-L1 Biomarker Testing Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-L1 Biomarker Testing Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

Read the full market overview

PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.

PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.

North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.

Report Includes

This report provides an overview of the global PD-L1 Biomarker Testing market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PD-L1 Biomarker Testing and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-L1 Biomarker Testing revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the PD-L1 Biomarker Testing market size, projected growth trends, production technologies, key applications, and end-use industries.

PD-L1 Biomarker Testing Segment by Company

Agilent Technologies

Roche

Merck

Bristol-Myers Squibb

AstraZeneca

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

PD-L1 Biomarker Testing Segment by Type

PD-L1 (22C3)

PD-L1(28-8)

PD-L1 (SP142)

PD-L1 (SP263)

Other

PD-L1 Biomarker Testing Segment by Application

Hospital

Diagnostic Center

Others

PD-L1 Biomarker Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 Biomarker Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-L1 Biomarker Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 Biomarker Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of PD-L1 Biomarker Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PD-L1 Biomarker Testing industry.

Chapter 3: Detailed analysis of PD-L1 Biomarker Testing companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-L1 Biomarker Testingrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global PD-L1 Biomarker Testing Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of PD-L1 (22C3) Table 3. Key Players of PD-L1(28-8) Table 4. Key Players of PD-L1 (SP142) Table 3. Key Players of PD-L1 (SP263) Table 4. Key Players of Other Table 5. Global PD-L1 Biomarker Testing Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Hospital Table 7. Key Players of Diagnostic Center Table 8. Key Players of Others Table 9. Global PD-L1 Biomarker Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global PD-L1 Biomarker Testing Market Size by Region (2021-2026) & (US$ Million) Table 11. Global PD-L1 Biomarker Testing Market Share by Region (2021-2026) Table 12. Global PD-L1 Biomarker Testing Market Size by Region (2027-2032) & (US$ Million) Table 13. Global PD-L1 Biomarker Testing Market Share by Region (2027-2032) Table 14. PD-L1 Biomarker Testing Industry Trends Table 15. PD-L1 Biomarker Testing Industry Drivers Table 16. PD-L1 Biomarker Testing Industry Opportunities and Challenges Table 17. PD-L1 Biomarker Testing Industry Restraints Table 18. Global PD-L1 Biomarker Testing Revenue by Company (US$ Million) & (2021-2026) Table 19. Global PD-L1 Biomarker Testing Revenue Market Share by Company (2021-2026) Table 20. Global PD-L1 Biomarker Testing Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global PD-L1 Biomarker Testing Key Company Head Office and Area Served Table 22. Global PD-L1 Biomarker Testing Company, Product Type & Application Table 23. Global PD-L1 Biomarker Testing Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global PD-L1 Biomarker Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global PD-L1 Biomarker Testing Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global PD-L1 Biomarker Testing Market Size by Type (2021-2026) & (US$ Million) Table 28. Global PD-L1 Biomarker Testing Market Size by Type (2027-2032) & (US$ Million) Table 29. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2021-2026) Table 30. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2027-2032) Table 31. Global PD-L1 Biomarker Testing Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global PD-L1 Biomarker Testing Market Size by Application (2021-2026) & (US$ Million) Table 33. Global PD-L1 Biomarker Testing Market Size by Application (2027-2032) & (US$ Million) Table 34. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2021-2026) Table 35. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2027-2032) Table 36. Agilent Technologies Company Information Table 37. Agilent Technologies Business Overview Table 38. Agilent Technologies PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Agilent Technologies PD-L1 Biomarker Testing Product Portfolio Table 40. Agilent Technologies Recent Development Table 41. Roche Company Information Table 42. Roche Business Overview Table 43. Roche PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Roche PD-L1 Biomarker Testing Product Portfolio Table 45. Roche Recent Development Table 46. Merck Company Information Table 47. Merck Business Overview Table 48. Merck PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Merck PD-L1 Biomarker Testing Product Portfolio Table 50. Merck Recent Development Table 51. Bristol-Myers Squibb Company Information Table 52. Bristol-Myers Squibb Business Overview Table 53. Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio Table 55. Bristol-Myers Squibb Recent Development Table 56. AstraZeneca Company Information Table 57. AstraZeneca Business Overview Table 58. AstraZeneca PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. AstraZeneca PD-L1 Biomarker Testing Product Portfolio Table 60. AstraZeneca Recent Development Table 61. Ono Pharmaceutical Company Information Table 62. Ono Pharmaceutical Business Overview Table 63. Ono Pharmaceutical PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio Table 65. Ono Pharmaceutical Recent Development Table 66. Regeneron Company Information Table 67. Regeneron Business Overview Table 68. Regeneron PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Regeneron PD-L1 Biomarker Testing Product Portfolio Table 70. Regeneron Recent Development Table 71. Innovent Company Information Table 72. Innovent Business Overview Table 73. Innovent PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Innovent PD-L1 Biomarker Testing Product Portfolio Table 75. Innovent Recent Development Table 76. Hengrui Medicine Company Information Table 77. Hengrui Medicine Business Overview Table 78. Hengrui Medicine PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio Table 80. Hengrui Medicine Recent Development Table 81. Junshi Biosciences Company Information Table 82. Junshi Biosciences Business Overview Table 83. Junshi Biosciences PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio Table 85. Junshi Biosciences Recent Development Table 86. North America PD-L1 Biomarker Testing Market Size by Type (2021-2026) & (US$ Million) Table 87. North America PD-L1 Biomarker Testing Market Size by Type (2027-2032) & (US$ Million) Table 88. North America PD-L1 Biomarker Testing Market Size by Application (2021-2026) & (US$ Million) Table 89. North America PD-L1 Biomarker Testing Market Size by Application (2027-2032) & (US$ Million) Table 90. North America PD-L1 Biomarker Testing Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. North America PD-L1 Biomarker Testing Market Size by Country (2021-2026) Table 92. North America PD-L1 Biomarker Testing Market Size by Country (2027-2032) Table 93. Europe PD-L1 Biomarker Testing Market Size by Type (2021-2026) & (US$ Million) Table 94. Europe PD-L1 Biomarker Testing Market Size by Type (2027-2032) & (US$ Million) Table 95. Europe PD-L1 Biomarker Testing Market Size by Application (2021-2026) & (US$ Million) Table 96. Europe PD-L1 Biomarker Testing Market Size by Application (2027-2032) & (US$ Million) Table 97. Europe PD-L1 Biomarker Testing Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Europe PD-L1 Biomarker Testing Market Size by Country (2021-2026) Table 99. Europe PD-L1 Biomarker Testing Market Size by Country (2027-2032) Table 100. China PD-L1 Biomarker Testing Market Size by Type (2021-2026) & (US$ Million) Table 101. China PD-L1 Biomarker Testing Market Size by Type (2027-2032) & (US$ Million) Table 102. China PD-L1 Biomarker Testing Market Size by Application (2021-2026) & (US$ Million) Table 103. China PD-L1 Biomarker Testing Market Size by Application (2027-2032) & (US$ Million) Table 104. Asia PD-L1 Biomarker Testing Market Size by Type (2021-2026) & (US$ Million) Table 105. Asia PD-L1 Biomarker Testing Market Size by Type (2027-2032) & (US$ Million) Table 106. Asia PD-L1 Biomarker Testing Market Size by Application (2021-2026) & (US$ Million) Table 107. Asia PD-L1 Biomarker Testing Market Size by Application (2027-2032) & (US$ Million) Table 108. Asia PD-L1 Biomarker Testing Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Asia PD-L1 Biomarker Testing Market Size by Country (2021-2026) Table 110. Asia PD-L1 Biomarker Testing Market Size by Country (2027-2032) Table 111. South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Type (2021-2026) & (US$ Million) Table 112. South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Type (2027-2032) & (US$ Million) Table 113. South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Application (2021-2026) & (US$ Million) Table 114. South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Application (2027-2032) & (US$ Million) Table 115. South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2021-2026) Table 117. South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. PD-L1 Biomarker Testing Product Image Figure 2. Global PD-L1 Biomarker Testing Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global PD-L1 Biomarker Testing Market Share by Type: 2025 VS 2032 Figure 4. PD-L1 (22C3) Image Figure 5. PD-L1(28-8) Image Figure 6. PD-L1 (SP142) Image Figure 7. PD-L1 (SP263) Image Figure 8. Other Image Figure 9. Global PD-L1 Biomarker Testing Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global PD-L1 Biomarker Testing Market Share by Application: 2025 VS 2032 Figure 11. Hospital Image Figure 12. Diagnostic Center Image Figure 13. Others Image Figure 14. Global PD-L1 Biomarker Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 16. Global PD-L1 Biomarker Testing Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global PD-L1 Biomarker Testing Market Share by Players in 2025 Figure 19. Global Top 5 and 10 PD-L1 Biomarker Testing Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global PD-L1 Biomarker Testing Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2021-2032) Figure 23. Global PD-L1 Biomarker Testing Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2021-2032) Figure 25. North America PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 26. North America PD-L1 Biomarker Testing Market Share by Type (2021-2032) Figure 27. North America PD-L1 Biomarker Testing Market Share by Application (2021-2032) Figure 28. North America PD-L1 Biomarker Testing Market Share by Country (2021-2032) Figure 29. United States PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 30. Canada PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 31. Mexico PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 32. Europe PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 33. Europe PD-L1 Biomarker Testing Market Share by Type (2021-2032) Figure 34. Europe PD-L1 Biomarker Testing Market Share by Application (2021-2032) Figure 35. Europe PD-L1 Biomarker Testing Market Share by Country (2021-2032) Figure 36. Germany PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 37. France PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 38. U.K. PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 39. Italy PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 40. Russia PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 42. China PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 43. China PD-L1 Biomarker Testing Market Share by Type (2021-2032) Figure 44. China PD-L1 Biomarker Testing Market Share by Application (2021-2032) Figure 45. Asia PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 46. Asia PD-L1 Biomarker Testing Market Share by Type (2021-2032) Figure 47. Asia PD-L1 Biomarker Testing Market Share by Application (2021-2032) Figure 48. Asia PD-L1 Biomarker Testing Market Share by Country (2021-2032) Figure 49. Japan PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 50. South Korea PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 53. India PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 54. Australia PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa PD-L1 Biomarker Testing Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa PD-L1 Biomarker Testing Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa PD-L1 Biomarker Testing Market Share by Country (2021-2032) Figure 59. Brazil PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 60. South Africa PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 62. Turkey PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 63. Argentina PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 64. UAE PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 65. Egypt PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 66. Chile PD-L1 Biomarker Testing Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • PD-L1 (22C3)
  • PD-L1(28-8)
  • PD-L1 (SP142)
  • PD-L1 (SP263)
  • Other
Applications
  • Hospital
  • Diagnostic Center
  • Others
Companies covered
  • Agilent Technologies
  • Roche
  • Merck
  • Bristol-Myers Squibb
  • AstraZeneca
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global PD-L1 Biomarker Testing Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 PD-L1 (22C3)
  5. 1.2.3 PD-L1(28-8)
  6. 1.2.4 PD-L1 (SP142)
  7. 1.2.5 PD-L1 (SP263)
  8. 1.2.6 Other
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global PD-L1 Biomarker Testing Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Diagnostic Center
  13. 1.3.4 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global PD-L1 Biomarker Testing Growth Trends by Region
  16. 1.5.1 Global PD-L1 Biomarker Testing Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 PD-L1 Biomarker Testing Market Size by Region (2021-2026)
  18. 1.5.3 PD-L1 Biomarker Testing Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global PD-L1 Biomarker Testing Market Dynamics
  1. 2.1 PD-L1 Biomarker Testing Industry Trends
  2. 2.2 PD-L1 Biomarker Testing Industry Drivers
  3. 2.3 PD-L1 Biomarker Testing Industry Opportunities and Challenges
  4. 2.4 PD-L1 Biomarker Testing Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global PD-L1 Biomarker Testing Revenue by Company (2021-2026)
  2. 3.2 Global PD-L1 Biomarker Testing Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global PD-L1 Biomarker Testing Key Company Head office and Area Served
  4. 3.4 Global PD-L1 Biomarker Testing Company, Product Type & Application
  5. 3.5 Global PD-L1 Biomarker Testing Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global PD-L1 Biomarker Testing Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 PD-L1 Biomarker Testing Players Market Share by Revenue in 2025
  9. 3.6.3 2025 PD-L1 Biomarker Testing Tier 1, Tier 2, and Tier 3
4 PD-L1 Biomarker Testing Market by Type
  1. 4.1 Global PD-L1 Biomarker Testing Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global PD-L1 Biomarker Testing Market Size by Type (2021-2032)
  3. 4.3 Global PD-L1 Biomarker Testing Market Size Share by Type (2021-2032)
5 PD-L1 Biomarker Testing Market by Application
  1. 5.1 Global PD-L1 Biomarker Testing Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global PD-L1 Biomarker Testing Market Size by Application (2021-2032)
  3. 5.3 Global PD-L1 Biomarker Testing Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Agilent Technologies
  2. 6.1.1 Agilent Technologies Company Information
  3. 6.1.2 Agilent Technologies Business Overview
  4. 6.1.3 Agilent Technologies PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Agilent Technologies PD-L1 Biomarker Testing Product Portfolio
  6. 6.1.5 Agilent Technologies Recent Developments
  7. 6.2 Roche
  8. 6.2.1 Roche Company Information
  9. 6.2.2 Roche Business Overview
  10. 6.2.3 Roche PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Roche PD-L1 Biomarker Testing Product Portfolio
  12. 6.2.5 Roche Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Merck PD-L1 Biomarker Testing Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 AstraZeneca PD-L1 Biomarker Testing Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 Ono Pharmaceutical
  32. 6.6.1 Ono Pharmaceutical Company Information
  33. 6.6.2 Ono Pharmaceutical Business Overview
  34. 6.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio
  36. 6.6.5 Ono Pharmaceutical Recent Developments
  37. 6.7 Regeneron
  38. 6.7.1 Regeneron Company Information
  39. 6.7.2 Regeneron Business Overview
  40. 6.7.3 Regeneron PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Regeneron PD-L1 Biomarker Testing Product Portfolio
  42. 6.7.5 Regeneron Recent Developments
  43. 6.8 Innovent
  44. 6.8.1 Innovent Company Information
  45. 6.8.2 Innovent Business Overview
  46. 6.8.3 Innovent PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Innovent PD-L1 Biomarker Testing Product Portfolio
  48. 6.8.5 Innovent Recent Developments
  49. 6.9 Hengrui Medicine
  50. 6.9.1 Hengrui Medicine Company Information
  51. 6.9.2 Hengrui Medicine Business Overview
  52. 6.9.3 Hengrui Medicine PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio
  54. 6.9.5 Hengrui Medicine Recent Developments
  55. 6.10 Junshi Biosciences
  56. 6.10.1 Junshi Biosciences Company Information
  57. 6.10.2 Junshi Biosciences Business Overview
  58. 6.10.3 Junshi Biosciences PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio
  60. 6.10.5 Junshi Biosciences Recent Developments
7 North America
  1. 7.1 North America PD-L1 Biomarker Testing Market Size (2021-2032)
  2. 7.2 North America PD-L1 Biomarker Testing Market Size by Type
  3. 7.2.1 North America PD-L1 Biomarker Testing Market Size by Type (2021-2026)
  4. 7.2.2 North America PD-L1 Biomarker Testing Market Size by Type (2027-2032)
  5. 7.2.3 North America PD-L1 Biomarker Testing Market Share by Type (2021-2032)
  6. 7.3 North America PD-L1 Biomarker Testing Market Size by Application
  7. 7.3.1 North America PD-L1 Biomarker Testing Market Size by Application (2021-2026)
  8. 7.3.2 North America PD-L1 Biomarker Testing Market Size by Application (2027-2032)
  9. 7.3.3 North America PD-L1 Biomarker Testing Market Share by Application (2021-2032)
  10. 7.4 North America PD-L1 Biomarker Testing Market Size by Country
  11. 7.4.1 North America PD-L1 Biomarker Testing Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America PD-L1 Biomarker Testing Market Size by Country (2021-2026)
  13. 7.4.3 North America PD-L1 Biomarker Testing Market Size by Country (2027-2032)
  14. 7.4.4 North America PD-L1 Biomarker Testing Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe PD-L1 Biomarker Testing Market Size (2021-2032)
  2. 8.2 Europe PD-L1 Biomarker Testing Market Size by Type
  3. 8.2.1 Europe PD-L1 Biomarker Testing Market Size by Type (2021-2026)
  4. 8.2.2 Europe PD-L1 Biomarker Testing Market Size by Type (2027-2032)
  5. 8.2.3 Europe PD-L1 Biomarker Testing Market Share by Type (2021-2032)
  6. 8.3 Europe PD-L1 Biomarker Testing Market Size by Application
  7. 8.3.1 Europe PD-L1 Biomarker Testing Market Size by Application (2021-2026)
  8. 8.3.2 Europe PD-L1 Biomarker Testing Market Size by Application (2027-2032)
  9. 8.3.3 Europe PD-L1 Biomarker Testing Market Share by Application (2021-2032)
  10. 8.4 Europe PD-L1 Biomarker Testing Market Size by Country
  11. 8.4.1 Europe PD-L1 Biomarker Testing Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe PD-L1 Biomarker Testing Market Size by Country (2021-2026)
  13. 8.4.3 Europe PD-L1 Biomarker Testing Market Size by Country (2027-2032)
  14. 8.4.4 Europe PD-L1 Biomarker Testing Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China PD-L1 Biomarker Testing Market Size (2021-2032)
  2. 9.2 China PD-L1 Biomarker Testing Market Size by Type
  3. 9.2.1 China PD-L1 Biomarker Testing Market Size by Type (2021-2026)
  4. 9.2.2 China PD-L1 Biomarker Testing Market Size by Type (2027-2032)
  5. 9.2.3 China PD-L1 Biomarker Testing Market Share by Type (2021-2032)
  6. 9.3 China PD-L1 Biomarker Testing Market Size by Application
  7. 9.3.1 China PD-L1 Biomarker Testing Market Size by Application (2021-2026)
  8. 9.3.2 China PD-L1 Biomarker Testing Market Size by Application (2027-2032)
  9. 9.3.3 China PD-L1 Biomarker Testing Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia PD-L1 Biomarker Testing Market Size (2021-2032)
  2. 10.2 Asia PD-L1 Biomarker Testing Market Size by Type
  3. 10.2.1 Asia PD-L1 Biomarker Testing Market Size by Type (2021-2026)
  4. 10.2.2 Asia PD-L1 Biomarker Testing Market Size by Type (2027-2032)
  5. 10.2.3 Asia PD-L1 Biomarker Testing Market Share by Type (2021-2032)
  6. 10.3 Asia PD-L1 Biomarker Testing Market Size by Application
  7. 10.3.1 Asia PD-L1 Biomarker Testing Market Size by Application (2021-2026)
  8. 10.3.2 Asia PD-L1 Biomarker Testing Market Size by Application (2027-2032)
  9. 10.3.3 Asia PD-L1 Biomarker Testing Market Share by Application (2021-2032)
  10. 10.4 Asia PD-L1 Biomarker Testing Market Size by Country
  11. 10.4.1 Asia PD-L1 Biomarker Testing Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia PD-L1 Biomarker Testing Market Size by Country (2021-2026)
  13. 10.4.3 Asia PD-L1 Biomarker Testing Market Size by Country (2027-2032)
  14. 10.4.4 Asia PD-L1 Biomarker Testing Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Type
  3. 11.2.1 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa PD-L1 Biomarker Testing Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Application
  7. 11.3.1 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa PD-L1 Biomarker Testing Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Country
  11. 11.4.1 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa PD-L1 Biomarker Testing Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst